Argenx Se, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on the stock and has a $887.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tazeen Ahmad’s rating is based on the promising results from Argenx’s phase 3 SERON study, which evaluated Vyvgart in patients with generalized myasthenia gravis (gMG). The study met its primary endpoint, demonstrating significant clinical improvements, which supports the expansion of Vyvgart’s label. This expansion is expected to bolster Vyvgart’s market leadership in gMG and accelerate its uptake, contributing to the company’s projected peak sales of $6.4 billion by 2034.
Additionally, Argenx’s robust pipeline, with several upcoming readouts across various indications, underpins the Buy rating. The company is actively working on expanding Vyvgart’s applications into other conditions, such as lupus nephritis and ocular MG, which could further enhance its market potential. The strategic development of these additional indications and the anticipated detailed results from the SERON study at an upcoming medical meeting provide a strong foundation for Argenx’s growth prospects, making it a top pick for 2025.
According to TipRanks, Ahmad is an analyst with an average return of -1.9% and a 51.22% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ascendis Pharma, and Argenx Se.
In another report released on August 26, Piper Sandler also maintained a Buy rating on the stock with a $820.00 price target.